Evidence map›Paper›PMID 35897143›Full record

ArticleJournal of the National Cancer Institute2022

Leadership Diversity and Development in the Nation's Cancer Centers.

Caryn Lerman, Chanita Hughes-Halbert, Mary Falcone, David M Gosky, Roy A Jensen, Kelvin P Lee, Edith Mitchell, Kunle Odunsi, Jennifer W Pegher, Elisa Rodriguez and 4 more

Abstract readEditorialComment
In one paragraph

Article in Journal of the National Cancer Institute, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Next in Line: Building a Succession Pipeline for Advanced Practitioners in Oncology.Journal of the advanced practitioner in oncology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Caryn LermanUniversity of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID 0000-0002-7553-8724
Chanita Hughes-HalbertUniversity of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID 0000-0002-0103-6916
Mary FalconeUniversity of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID 0000-0002-8451-2438
David M GoskyThe Ohio State University Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA.
Roy A JensenUniversity of Kansas Cancer Center, University of Kansas, Kansas City, KS, USA.ORCID 0000-0003-4430-2281
Kelvin P LeeIndiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University, Indianapolis, IN, USA.
Edith MitchellThomas Jefferson University Kimmel Cancer Center, Philadelphia, PA, USA.ORCID 0000-0002-6788-7086
Kunle OdunsiUniversity of Chicago Medicine Comprehensive Cancer Center, University of Chicago Medicine, Chicago, IL, USA.
Jennifer W PegherAssociation of American Cancer Institutes, Pittsburgh, PA, USA.
Elisa RodriguezRoswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Yolanda SanchezNorris Cotton Cancer Center, Dartmouth Geisel School of Medicine, Hanover, NH, USA.
Reuben ShawSalk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0000-0002-1555-8977
George WeinerHolden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.ORCID 0000-0003-3427-0562
Cheryl L WillmanMayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN, USA.

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Lila J. Rutten · 1985 to 2026
$151.3M
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
VIRAL ONCOLOGY CORE FACILITYP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI KUNLE ODUNSI · 1985 to 2026
$122.1M
Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI CANDACE S JOHNSON · 1985 to 2026
$116.6M
Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Fred W Kolling IV · 1985 to 2026
$91.3M
Viral Vector Core (VVC)P30CA014195 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Alan Saghatelian · 1985 to 2026
$82.8M
Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Jon C.D. Houtman · 2000 to 2026
$70.0M
Tumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI David W Clapp · 1999 to 2026
$59.3M
Transgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ROY A. JENSEN · 2012 to 2026
$40.1M
University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Jennifer F Rogers · 2013 to 2026
$38.3M
NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA014195NCI NIH HHS P30 CA014599NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA016056NCI NIH HHS P30 CA016058NCI NIH HHS P30 CA023108NCI NIH HHS P30 CA082709NCI NIH HHS P30 CA086862NCI NIH HHS P30 CA168524NCI NIH HHS P30 CA177558
6 · The paper itself

Abstract

The capacity and diversity of the oncology leadership workforce has not kept pace with the emerging needs of our increasingly complex cancer centers and the spectrum of challenges our institutions face in reducing the cancer burden in diverse catchment areas. Recognizing the importance of a diverse workforce to reduce cancer inequities, the Association of American Cancer Institutes conducted a survey of its 103 cancer centers to examine diversity in leadership roles from research program leaders to cancer center directors. A total of 82 (80%) centers responded, including 64 National Cancer Institute-designated and 18 emerging centers. Among these 82 respondents, non-Hispanic White individuals comprised 79% of center directors, 82% of deputy directors, 72% of associate directors, and 72% of program leaders. Women are underrepresented in all leadership roles (ranging from 16% for center directors to 45% for associate directors). Although the limited gender, ethnic, and racial diversity of center directors and perhaps deputy directors is less surprising, the demographics of current research program leaders and associate directors exposes a substantial lack of diversity in the traditional cancer center senior leadership pipeline. Sole reliance on the cohort of current center leaders and leadership pipeline is unlikely to produce the diversity in cancer center leadership needed to facilitate the ability of those centers to address the needs of the diverse populations they serve. Informed by these data, this commentary describes some best practices to build a pipeline of emerging leaders who are representative of the diverse populations served by these institutions and who are well positioned to succeed.

Indexed as

LeadershipNeoplasmsFemaleHumansNational Cancer Institute (U.S.)Racial GroupsUnited States

Identifiers

PMID35897143
PMCPMC9468284

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.